Department of Obstetrics and Gynecology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan.
Department of Obstetrics and Gynecology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan
Anticancer Res. 2023 Aug;43(8):3787-3792. doi: 10.21873/anticanres.16564.
BACKGROUND/AIM: Platinum-based drugs are the standard treatment for ovarian cancer, and platinum resistance is a major problem. A previous study has reported that the UBE2L6 expression is elevated in cisplatin-resistant cells, which in turn leads to cisplatin resistance by modulating the transcriptional expression of ABCB6. The present study aimed to investigate the expression of UBE2L6 and ABCB6 in ovarian carcinoma and to evaluate the association between these markers and platinum resistance.
Ninety-two patients diagnosed with serous ovarian carcinoma (SOC) were enrolled in this study. Tissue samples were collected from these patients and analysed using immunohistochemistry to assess the expression of UBE2L6 and ABCB6.
UBE2L6 and ABCB6 staining was positive in 41 (44.6%) and 46 (50.0%) cases, respectively. UBE2L6 expression was statistically significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage (p=0.008). Both UBE2L6 and ABCB6 were significantly associated with platinum sensitivity (p<0.001 and p<0.001). A positive correlation was observed between the expression levels of UBE2L6 and ABCB6 (r=0.673, p<0.001). Progression-free survival (PFS) was significantly longer in the UBE2L6 negative group than that in the positive group (median PFS, 31.4 vs. 11.1 months, p<0.01) and in the ABCB6 negative group than that in the positive group (median PFS, 29.6 vs. 12.2 months, p<0.01).
UBE2L6 and ABCB6 expression is associated with the prognosis of SOC. UBE2L6 and ABCB6 may be potential biomarkers of platinum-resistant ovarian cancer.
背景/目的：铂类药物是卵巢癌的标准治疗药物，而铂类耐药是一个主要问题。先前的研究报道，在顺铂耐药细胞中 UBE2L6 的表达上调，进而通过调节 ABCB6 的转录表达导致顺铂耐药。本研究旨在探讨 UBE2L6 和 ABCB6 在卵巢癌中的表达，并评估这些标志物与铂类耐药之间的关系。
本研究纳入了 92 例诊断为浆液性卵巢癌（SOC）的患者。采集这些患者的组织样本，并用免疫组织化学法分析，以评估 UBE2L6 和 ABCB6 的表达。
UBE2L6 和 ABCB6 的染色阳性分别为 41（44.6%）和 46（50.0%）例。UBE2L6 的表达与国际妇产科联合会（FIGO）分期显著相关（p=0.008）。UBE2L6 和 ABCB6 均与铂类敏感性显著相关（p<0.001 和 p<0.001）。UBE2L6 的表达水平与 ABCB6 呈正相关（r=0.673，p<0.001）。UBE2L6 阴性组的无进展生存期（PFS）明显长于阳性组（中位 PFS，31.4 与 11.1 个月，p<0.01），而 ABCB6 阴性组的 PFS 明显长于阳性组（中位 PFS，29.6 与 12.2 个月，p<0.01）。
UBE2L6 和 ABCB6 的表达与 SOC 的预后相关。UBE2L6 和 ABCB6 可能是铂类耐药卵巢癌的潜在生物标志物。
